← BackINTEGRATED BIOPHARMA INC · DrugmakersINBP
Moderate riskNext report: Around Feb 10, 2027 (est.)
The short versionA profitable company with shrinking sales.
Going well
- Profitable
- Brings in more cash than it spends
- Buying back shares: share count down 3.6% in 3 years
Watch out for
- Sales down 31% in the latest quarter vs a year ago
Money moves
- No insider buying or selling in the last 30 days
Facts from SEC filings, not a recommendation.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26 (worked out from yearly totals)$9.8M-31% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $43.9M, down 19% from the 12 months before. Over 5 years, sales grew about 0.6% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.8.2%
- PassDebt under half of equityNot relying on borrowed money.No debt reported
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.1.5%
- MissProfitable every yearSteady profits, not one good year.8 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$1.9M
- PassShare count not growingNot diluting owners. Falling means buybacks.-3.6% in 3 years
- MissGross margin 40%+Pricing power: sells for well above what it costs to make.10.2%
- Revenue
- $54.4M
- +8.0% vs prior year
- 5-year growth
- +0.6%/yr
- revenue, per year
- Total debt
- None
- 0.00x equity
- Current ratio
- 5.03x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $9.8M
- -30.9% YoY
- EPS
- -$0.04
- vs $0.00
- Op. margin
- -8.9%
- -13.1 pts
- Gross margin
- 0.3%
- -10.1 pts
- Free cash flow
- -$1.3M
Some values are worked out from year-to-date totals in the annual report.
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.2
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Share count growthYearly rate, last 3 years
+1.2%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
No debt reportedShares outstandingLatest reported
31MWhy moderate risk- Losing money
- Revenue down 19.3% from the year before
Next reportAround Feb 10, 2027 (est.)Estimated from the same quarter last year
- Results filedSep 25
- Results filedMay 8
- Results filedFeb 11
- Results filedNov 10, 2025
- Results filedSep 23, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Stock awardWilliam H. MilmoeDirector
50,000 shares
- Now owns 50,000 shares
- Exercise price $0.19
- Stock Option (Right to Buy)
- Filed 1 day after trade
Stock awardRobert CanarickDirector
50,000 shares
- Now owns 50,000 shares
- Exercise price $0.19
- Stock Option (Right to Buy)
- Filed 1 day after trade
Stock awardEric J FriedmanDirector
50,000 shares
- Now owns 50 shares
- Exercise price $0.19
- Stock Option (Right to Buy)
- Filed 1 day after trade
Stock awardDamon DesantisDirector, 10% owner
50,000 shares
- Now owns 50,000 shares
- Exercise price $0.20
- Stock Option (Right to Buy)
- Filed 1 day after trade
Stock awardEric J FriedmanDirector
50,000 shares
- Now owns 50,000 shares
- Exercise price $0.19
- Stock Option (Right to Buy)
- Filed 1 day after trade
GiftDamon DesantisDirector, 10% owner
11,201,964 shares
- +732% of holdings
- Now owns 12,733,058 shares
- Held by CDDS 2.0, LLC
- 2 transactions
- Filed 2 days after trade